Richard Prince, Ph.D.

Regulatory and Clinical Advisor

Richard Prince, Ph.D., is the Regulatory and Clinical Advisor to South Rampart Pharma. He is the Founder/CEO of Now Biopharma, LLC, a Clinical CRO, and life science consultancy specializing in performing Phase-2, -3, and -4 acute care clinical trials, such as neurology and cardiovascular diseases. He has extensive expertise in strategy, scientific affairs, regulatory affairs, clinical development, facilitation, and quality operations.  Dr. Prince’s 35-year career in the industry includes multivariate management/executive roles, spanning startup to commercial companies, small molecule, and large molecule programs, and being on both the service and product sectors of the healthcare industry. Dr. Prince received his B.A. (Microbiology) and Ph.D. (Zoology & Physiology specializing in Tumor Immunology) from Rutgers University. Dr. Prince is a well-known author and editor within the Parenteral Drug Association (PDA) community, with five published textbooks in microbiology, quality, variability, and biotechnology (2019). His microbiology text remains the top-selling text in the history of the PDA. Dr. Prince previously worked at Gibraltar Laboratories (a CRO), Microgen, Inc. (a specialty chemical firm), Mayne Pharma (Australia’s largest healthcare company, now part of Pfizer), and Prolong Pharmaceuticals (a hematology and oncology biotech startup), where he was a direct report to Dr. Abraham Abuchowski, inventor of PEGylation. Dr. Prince has consulted extensively for industry, including multiple ‘Big Pharma’ companies operating under Warning Letters and Consent Decrees issued by the FDA. Dr. Prince is a well-known author and editor within the Parenteral Drug Association (PDA) community, with five published textbooks in the areas of microbiology (2001; 2008), which remains the top-selling text in the history of the PDA, quality (2004), variability (2008), and most recently, Biotechnology: From Idea to Market (2019).